Download PDF
Kinder- und Jugendmedizin 2010; 10(02): 123
DOI: 10.1055/s-0038-1629059
Methylphenidat
Schattauer GmbH

Literatur

Further Information

Publication History

Publication Date:
25 January 2018 (online)

    Permissions and Reprints

 

 

  • Literatur

  • 1 Arakawa R. et al. Quantitative analysis of norepinephrine transporter in the human brain using PET with (S,S)-18F-FMeNER-D2. J Nucl Med 2008; 49: 1270-1276.
    CrossrefPubMedGoogle Scholar
  • 2 Berridge CW. et al. Methylphenidate preferentially increases catecholamine neurotransmission within the prefrontal cortex at low doses that enhance cognitive function. Biol Psychiatry 2006; 60: 1111-1120.
    CrossrefPubMedGoogle Scholar
  • 3 Brown TE. Attention-deficit disorders and comorbidities in children, adolescents, and adults. Washington, London: American Psychiatric Press; 2000
    Google Scholar
  • 4 Drouin C, Page M, Waterhouse B. Methylphenidate enhances noradrenergic transmission and suppresses mid- and long-latency sensory responses in the primary somatosensory cortex of awake rats. J Neurophysiol 2006; 96: 622-632.
    CrossrefPubMedGoogle Scholar
  • 5 Gerlach M. Pharmakologie von Methylphenidat. In: Schulte-Markwort M, Warnke A. (Hrsg). Methylphenidat. Stuttgart: Thieme; 2004
    Google Scholar
  • 6 Han DD, Gu HH. Comparison of the monoamine transporters from human and mouse in their sensitivities to psychostimulant drugs. BMC Pharmacol 2006; 6: 6.
    PubMedGoogle Scholar
  • 7 Horner WE. et al. Methylphenidate and atomo -xetine increase histamine release in rat prefrontal cortex. Eur J Pharmacol 2007; 558: 96-97.
    CrossrefPubMedGoogle Scholar
  • 8 Ishimatsu M. et al. Effects of methylphenidate on the membrane potential and current in neurons of the rat locus coeruleus. J Neurophysiol 2002; 87: 1206-1212.
    CrossrefPubMedGoogle Scholar
  • 9 Kim CH. et al. A polymorphism in the norepine -phrine transporter gene alters promoter activity and is associated with attention-deficit hyperacti -vity disorder. PNAS 2006; 103: 19164-19169.
    CrossrefPubMedGoogle Scholar
  • 10 Krause J. SPECT and PET of the dopamine transporter in attention-deficit/hyperactivity disorder. Expert Rev Neurother 2008; 8: 611-625.
    CrossrefPubMedGoogle Scholar
  • 11 Krause J. et al. Influence of striatal dopamine transporter availability on the response to methylphenidate in adult patients with ADHD. Eur Arch Psychiatry Clin Neurosci 2005; 255: 428-431.
    CrossrefPubMedGoogle Scholar
  • 12 Krause KH. et al. Increased striatal dopamine transporter in adult patients with attention deficit hyperactivity disorder: Effects of methylphenidate as measured by single photon emission computed tomography. Neurosci Lett 2000; 285: 107-110.
    CrossrefPubMedGoogle Scholar
  • 13 Tzavara ET. et al. Procholinergic and memory enhancing properties of the selective norepinephrine uptake inhibitor atomoxetine. Mol Psychiatry 2006; 11: 187-195.
    CrossrefPubMedGoogle Scholar
  • 14 Volkow ND. et al. Dopamine transporter occupancies in the human brain induced by therapeutic doses of oral methylphenidate. Am J Psychiatry 1998; 155: 1325-1331.
    CrossrefPubMedGoogle Scholar
  • 15 Wilens TE. Effects of methylphenidate on the catecholaminergic system in attention-deficit/hyperactivity disorder. J Clin Psychopharmacol 2008; 28 (02) S46-53.
    CrossrefPubMedGoogle Scholar
  • 16 Wilens TE, Decker MW. Neuronal nicotinic receptor agonists for the treatment of attention-deficit/ hyperactivity disorder: focus on cognition. Biochem Pharmacol 2007; 74: 1212-1223.
    CrossrefPubMedGoogle Scholar
  • 17 Yang L, Wang YF, Li J, Faraone SV. Association of norepinephrine transporter gene with methylphenidate response. J Am Acad Child Adolesc Psychiatry 2004; 43: 1154-1158.
    CrossrefPubMedGoogle Scholar